Lee Sul-Hee, Bae Youin, Park Young-Lip
Department of Dermatology, Soon Chun Hyang University Bucheon Hospital, Bucheon 14584, Korea.
Department of Dermatology, College of Medicine, Hallym University, Hallym University Dongtan Sacred Heart Hospital, Hwaseong 18450, Korea.
J Clin Med. 2022 Oct 24;11(21):6255. doi: 10.3390/jcm11216255.
Atopic dermatitis (AD) is characterized by chronic, relapsing, pruritic inflammatory skin disease. Adiponectin has been reported to have anti-inflammatory effects not only on metabolic disorders but also on various inflammatory disorders. The study aimed to validate adiponectin as a potential biomarker for AD disease severity and treatment response. Seventy-five patients with AD and 28 healthy volunteers were enrolled in the study. Patient information, including Eczema Area and Severity Index (EASI) scores and pruritus numeric rating scales (NRSs), were collected. An enzyme linked immunosorbent assay (ELISA) was conducted to measure levels of serum adiponectin. Additionally, sera of patients treated with dupilumab were collected and measured at 16 and 52 weeks from baseline. Serum adiponectin levels were significantly lower in moderate and severe AD patients than in the control and mild AD patients. Serum adiponectin level was negatively correlated with the EASI score and pruritus NRS. However, no significant changes were observed according to biologic treatment for AD. Low serum adiponectin levels are associated with moderate to severe AD, suggesting a potential role for adiponectin as a biomarker for severity assessment of AD.
特应性皮炎（AD）的特征是慢性、复发性、瘙痒性炎症性皮肤病。据报道，脂联素不仅对代谢紊乱有抗炎作用，而且对各种炎症性疾病也有抗炎作用。该研究旨在验证脂联素作为AD疾病严重程度和治疗反应的潜在生物标志物。75例AD患者和28名健康志愿者参与了该研究。收集了患者信息，包括湿疹面积和严重程度指数（EASI）评分以及瘙痒数字评定量表（NRS）。采用酶联免疫吸附测定（ELISA）法检测血清脂联素水平。此外，收集了接受度普利尤单抗治疗的患者在基线后16周和52周的血清并进行检测。中度和重度AD患者的血清脂联素水平显著低于对照组和轻度AD患者。血清脂联素水平与EASI评分和瘙痒NRS呈负相关。然而，AD生物治疗后未观察到显著变化。低血清脂联素水平与中度至重度AD相关，提示脂联素作为AD严重程度评估生物标志物的潜在作用。
